Durvalumab

立即咨询

Durvalumab

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

1428935-60-7

德瓦鲁单抗
MEDI 4736

Durvalumab (MEDI 4736) 是一种人源化的抗PD-L1蛋白单克隆抗体。Durvalumab (MEDI 4736) 完全阻断PD-L1与PD-1和CD80结合，IC₅₀分别为 0.1 和 0.04 nM。

生物活性

Durvalumab (MEDI 4736) is an humanized anti-PD-L1monoclonal antibody^[1]. Durvalumab (MEDI4736) completely blocks the binding ofPD-L1to bothPD-1andCD80, withIC₅₀s of 0.1 and 0.04 nM, respectively^[2].

IC₅₀& Target

IC50: 0.1 nM (PD-L1/PD-1), 0.04 nM (PD-L1/CD80)^[2]

体内研究
(In Vivo)

Durvalumab inhibits tumor growth in mouse xenograft models of human melanoma (A375) and pancreatic (HPAC) tumour cell lines, via a T-cell-mediated mechanism. Durvalumab (5-0.01 mg/kg for NOD/SCID mice with HPAC tumor; 5-0.1 mg/kg for NOD/SCID mice with A375 tumor; administration i.p.; twice per week; for 3 weeks) significantly inhibits the tumor growth of both HPAC and A375 xenografts compared with an isotype-matched control antibody. Tumor growth inhibition of the HPAC cells reaches 74%, whereas inhibition of the A375 cells reaches 77%. When administered in the absence of T cells, Durvalumab has no effect on the growth of the A375 tumor xenograft^[2].

Animal Model:	NOD/SCID mice with HPAC tumor, following coimplantation of primary human T cells; NOD/SCID mice with A375 tumor, following coimplantation of primary human T cells^[2]
Dosage:	5, 1, 0.1, and 0.01 mg/kg for NOD/SCID mice with HPAC tumor; 5, 1, and 0.1 mg/kg for NOD/SCID mice with A375 tumor
Administration:	Administration i.p.; twice per week; for 3 weeks
Result:	Significantly inhibited the tumor growth of both HPAC and A375 xenografts compared with an isotype-matched control antibody.

Clinical Trial

性状

Liquid

CAS 号

1428935-60-7

中文名称

度伐单抗；德瓦鲁单抗

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.